Logo image of INFU

INFUSYSTEM HOLDINGS INC (INFU) Stock Fundamental Analysis

NYSEARCA:INFU - NYSE Arca - US45685K1025 - Common Stock - Currency: USD

5.95  -0.16 (-2.62%)

After market: 5.95 0 (0%)

Fundamental Rating

6

Taking everything into account, INFU scores 6 out of 10 in our fundamental rating. INFU was compared to 102 industry peers in the Health Care Providers & Services industry. INFU has an excellent profitability rating, but there are some minor concerns on its financial health. INFU is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, INFU could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year INFU was profitable.
In the past year INFU had a positive cash flow from operations.
Each year in the past 5 years INFU has been profitable.
In the past 5 years INFU always reported a positive cash flow from operatings.
INFU Yearly Net Income VS EBIT VS OCF VS FCFINFU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

With a decent Return On Assets value of 3.06%, INFU is doing good in the industry, outperforming 64.71% of the companies in the same industry.
INFU has a Return On Equity of 5.78%. This is in the better half of the industry: INFU outperforms 62.75% of its industry peers.
INFU has a better Return On Invested Capital (7.47%) than 72.55% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INFU is significantly below the industry average of 9.62%.
The last Return On Invested Capital (7.47%) for INFU is above the 3 year average (3.86%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.06%
ROE 5.78%
ROIC 7.47%
ROA(3y)1.04%
ROA(5y)4.49%
ROE(3y)1.93%
ROE(5y)10.25%
ROIC(3y)3.86%
ROIC(5y)4.73%
INFU Yearly ROA, ROE, ROICINFU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

With a decent Profit Margin value of 2.32%, INFU is doing good in the industry, outperforming 62.75% of the companies in the same industry.
INFU's Profit Margin has been stable in the last couple of years.
The Operating Margin of INFU (6.07%) is better than 63.73% of its industry peers.
In the last couple of years the Operating Margin of INFU has grown nicely.
INFU's Gross Margin of 53.13% is fine compared to the rest of the industry. INFU outperforms 78.43% of its industry peers.
INFU's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.07%
PM (TTM) 2.32%
GM 53.13%
OM growth 3Y22.87%
OM growth 5Y3.29%
PM growth 3Y7.83%
PM growth 5Y0.72%
GM growth 3Y-3.89%
GM growth 5Y-2.01%
INFU Yearly Profit, Operating, Gross MarginsINFU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), INFU is destroying value.
INFU has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, INFU has more shares outstanding
Compared to 1 year ago, INFU has an improved debt to assets ratio.
INFU Yearly Shares OutstandingINFU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INFU Yearly Total Debt VS Total AssetsINFU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.52 indicates that INFU is not a great score, but indicates only limited risk for bankruptcy at the moment.
INFU has a Altman-Z score (2.52) which is in line with its industry peers.
INFU has a debt to FCF ratio of 12.54. This is a negative value and a sign of low solvency as INFU would need 12.54 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 12.54, INFU is in line with its industry, outperforming 44.12% of the companies in the same industry.
INFU has a Debt/Equity ratio of 0.52. This is a neutral value indicating INFU is somewhat dependend on debt financing.
With a decent Debt to Equity ratio value of 0.52, INFU is doing good in the industry, outperforming 60.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 12.54
Altman-Z 2.52
ROIC/WACC0.88
WACC8.46%
INFU Yearly LT Debt VS Equity VS FCFINFU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 2.21 indicates that INFU has no problem at all paying its short term obligations.
The Current ratio of INFU (2.21) is better than 77.45% of its industry peers.
A Quick Ratio of 1.83 indicates that INFU should not have too much problems paying its short term obligations.
INFU has a Quick ratio of 1.83. This is in the better half of the industry: INFU outperforms 70.59% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 1.83
INFU Yearly Current Assets VS Current LiabilitesINFU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

7

3. Growth

3.1 Past

INFU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6900.00%, which is quite impressive.
The Earnings Per Share has been growing by 10.59% on average over the past years. This is quite good.
INFU shows a small growth in Revenue. In the last year, the Revenue has grown by 7.98%.
Measured over the past years, INFU shows a quite strong growth in Revenue. The Revenue has been growing by 10.70% on average per year.
EPS 1Y (TTM)6900%
EPS 3Y12.62%
EPS 5Y10.59%
EPS Q2Q%80%
Revenue 1Y (TTM)7.98%
Revenue growth 3Y9.62%
Revenue growth 5Y10.7%
Sales Q2Q%8.5%

3.2 Future

The Earnings Per Share is expected to grow by 84.76% on average over the next years. This is a very strong growth
INFU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.03% yearly.
EPS Next Y80.2%
EPS Next 2Y84.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.04%
Revenue Next 2Y8.03%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
INFU Yearly Revenue VS EstimatesINFU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
INFU Yearly EPS VS EstimatesINFU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2020 2021 2022 2023 2024 2025 2026 0 0.1 0.2 0.3 0.4

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 42.50, which means the current valuation is very expensive for INFU.
INFU's Price/Earnings is on the same level as the industry average.
INFU is valuated expensively when we compare the Price/Earnings ratio to 26.53, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 17.43, INFU is valued on the expensive side.
Based on the Price/Forward Earnings ratio, INFU is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
INFU's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.27.
Industry RankSector Rank
PE 42.5
Fwd PE 17.43
INFU Price Earnings VS Forward Price EarningsINFU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INFU is valued cheaper than 83.33% of the companies in the same industry.
INFU's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 54.54
EV/EBITDA 7.15
INFU Per share dataINFU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

INFU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INFU has a very decent profitability rating, which may justify a higher PE ratio.
INFU's earnings are expected to grow with 84.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.53
PEG (5Y)4.01
EPS Next 2Y84.76%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

INFU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

INFUSYSTEM HOLDINGS INC

NYSEARCA:INFU (6/9/2025, 8:04:00 PM)

After market: 5.95 0 (0%)

5.95

-0.16 (-2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners78.82%
Inst Owner Change-0.34%
Ins Owners3.62%
Ins Owner Change0.69%
Market Cap124.83M
Analysts84
Price Target13.9 (133.61%)
Short Float %2.04%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.72%
Min EPS beat(2)-48.06%
Max EPS beat(2)75.49%
EPS beat(4)2
Avg EPS beat(4)7.91%
Min EPS beat(4)-48.06%
Max EPS beat(4)75.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-4.92%
Max Revenue beat(2)0.99%
Revenue beat(4)2
Avg Revenue beat(4)-1.04%
Min Revenue beat(4)-4.92%
Max Revenue beat(4)0.99%
Revenue beat(8)5
Avg Revenue beat(8)0.79%
Revenue beat(12)6
Avg Revenue beat(12)-0.71%
Revenue beat(16)7
Avg Revenue beat(16)-1.97%
PT rev (1m)-3.54%
PT rev (3m)-3.54%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)-20.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-35.4%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 42.5
Fwd PE 17.43
P/S 0.91
P/FCF 54.54
P/OCF 5.71
P/B 2.26
P/tB 2.76
EV/EBITDA 7.15
EPS(TTM)0.14
EY2.35%
EPS(NY)0.34
Fwd EY5.74%
FCF(TTM)0.11
FCFY1.83%
OCF(TTM)1.04
OCFY17.51%
SpS6.56
BVpS2.63
TBVpS2.16
PEG (NY)0.53
PEG (5Y)4.01
Profitability
Industry RankSector Rank
ROA 3.06%
ROE 5.78%
ROCE 9.46%
ROIC 7.47%
ROICexc 7.6%
ROICexgc 8.58%
OM 6.07%
PM (TTM) 2.32%
GM 53.13%
FCFM 1.66%
ROA(3y)1.04%
ROA(5y)4.49%
ROE(3y)1.93%
ROE(5y)10.25%
ROIC(3y)3.86%
ROIC(5y)4.73%
ROICexc(3y)3.88%
ROICexc(5y)5.02%
ROICexgc(3y)4.43%
ROICexgc(5y)5.92%
ROCE(3y)4.88%
ROCE(5y)5.98%
ROICexcg growth 3Y31.39%
ROICexcg growth 5Y0.4%
ROICexc growth 3Y34.21%
ROICexc growth 5Y4.6%
OM growth 3Y22.87%
OM growth 5Y3.29%
PM growth 3Y7.83%
PM growth 5Y0.72%
GM growth 3Y-3.89%
GM growth 5Y-2.01%
F-Score9
Asset Turnover1.32
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 12.54
Debt/EBITDA 1.35
Cap/Depr 151.51%
Cap/Sales 14.23%
Interest Coverage 250
Cash Conversion 102.77%
Profit Quality 71.76%
Current Ratio 2.21
Quick Ratio 1.83
Altman-Z 2.52
F-Score9
WACC8.46%
ROIC/WACC0.88
Cap/Depr(3y)114.8%
Cap/Depr(5y)115.78%
Cap/Sales(3y)11.93%
Cap/Sales(5y)13.88%
Profit Quality(3y)4561.75%
Profit Quality(5y)2764.31%
High Growth Momentum
Growth
EPS 1Y (TTM)6900%
EPS 3Y12.62%
EPS 5Y10.59%
EPS Q2Q%80%
EPS Next Y80.2%
EPS Next 2Y84.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.98%
Revenue growth 3Y9.62%
Revenue growth 5Y10.7%
Sales Q2Q%8.5%
Revenue Next Year8.04%
Revenue Next 2Y8.03%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y149.37%
EBIT growth 3Y34.69%
EBIT growth 5Y14.35%
EBIT Next Year297.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y177.23%
FCF growth 3Y16.52%
FCF growth 5YN/A
OCF growth 1Y64.52%
OCF growth 3Y3.76%
OCF growth 5Y8.08%